Latest news with #BauschLomb
National Post
01-07-2025
- Health
- National Post
Bausch + Lomb Combines Patient Voices and New Survey Insights to Combat Persistent Misconceptions about Dry Eye
Article content New survey data reinforces the importance of ongoing awareness and education to help dry eye sufferers seek relief sooner Eyes Tell the Story campaign aims to close the awareness gap through personal stories and portraits of those living with dry eye Additional information and dry eye resources available at including opportunity to share your own dry eye story Article content VAUGHAN, Ontario — Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today launched ' Eyes Tell the Story: The Impact of Dry Eye.' The campaign aims to educate about dry eye through personal stories, compelling imagery and new survey data, and encourages people with symptoms to speak with their eye doctor to find relief. Article content Article content Eyes Tell the Story Article content builds upon Article content , an educational campaign launched in 2024 that featured data and insights from the company's first Article content State of Dry Eye Article content survey Article content , which showed the majority of Americans may not know that their eye symptoms are associated with eye dryness, despite the growing prevalence of dry eye. This year's survey, conducted among dry eye sufferers who are using either a prescription treatment or over-the-counter (OTC) product, further supports the need for more patient education and to dispel ongoing misconceptions surrounding dry eye. Key findings include: Article content The majority (78%) of sufferers strongly or somewhat agree they wish they had more resources and education on dry eye Despite most sufferers feeling satisfied in their personal understanding of dry eye, 62% of sufferers mistakenly assume or aren't sure if dry eye resolves itself after some treatment, including 68% of OTC users and 53% of prescription users 43% of sufferers incorrectly thought or weren't sure dry eye was a temporary condition and 42% didn't know or weren't sure it requires long-term treatment Article content The cornerstone of Eyes Tell the Story is a collaboration with photographer and artist Kayte Demont, who has captured portraits of those like her who are living with the daily disruptions of dry eye symptoms. Featured in Kayte's work are Alvin Wayne, an interior designer, lifestyle content creator and men's health advocate whose dry eye symptoms are exacerbated by long working hours, and Brianne Manz, a fashion, lifestyle and parenting blogger, whose symptoms are aggravated by excessive screen time. Kayte, Alvin and Brianne are sharing their stories to help close the awareness gap that exists around dry eye. Article content This year's campaign reinforces that there are a range of potential relief options available that may be appropriate depending on the cause, severity and frequency of dry eye symptoms. Dry eye can affect anyone. If someone is particularly aware of how their eyes feel, it may be a sign of dry eye symptoms, and it's important to consult an eye doctor. Article content 'Approximately 150 million U.S. adults experience occasional or frequent symptoms of dry eye, with around 38 million living with chronic dry eye, also known as dry eye disease,' said Yehia Hashad, MD, executive vice president, Research & Development and chief medical officer, Bausch + Lomb. ' By spotlighting these personal stories, we hope to help more people recognize their dry eye symptoms sooner so they will seek and find relief.' 1,2 The survey also underscores the importance of encouraging proactive dry eye management and for patients to work with their eye doctor to determine the appropriate relief options: Article content 'Don't delay,' said Hashad. 'Relief can come in many forms – from over-the-counter drops and nutritional supplements to prescription treatments from a doctor – but the sooner you seek relief, the better.' Article content To learn more about the Eyes Tell the Story campaign, visit where you can find additional information and dry eye resources. You can also share your own dry eye story via the website, with the potential to be featured in next year's Dry Eye Awareness Month (July) campaign. Article content About Dry Eye Article content Dry eye can be influenced by several factors, including lifestyle, medications, hormonal changes, age, environment and co-morbidities. It may be the result of the eyes not making enough tears or making poor quality tears that evaporate too quickly. The majority of those who progress to dry eye disease also have underlying inflammation. There are a range of options for managing dry eye symptoms, including over-the-counter eye drops, prescription medications and nutritional supplements. Article content About the Survey Article content The research was conducted online in the U.S. by The Harris Poll on behalf of Bausch + Lomb among 732 U.S. adults aged 18 or older considered 'DED sufferers' (defined as those who often/always experience eye dryness or have been diagnosed by a healthcare professional with dry eye disease). Of those 732,347 take only an over-the-counter product to treat their dry eye and 385 take a prescription medication for their dry eye. The survey was conducted between March 24 and April 21, 2025. Article content Data are weighted where necessary by age by gender, race/ethnicity, region, education, marital status, household size, employment, household income and political party affiliation to bring them in line with their actual proportions in the population. Article content Respondents for this survey were selected from among those who have agreed to participate in our surveys. The sampling precision of Harris online polls is measured by using a Bayesian credible interval. For this study, the sample data is accurate to within ±4.8 using a 95% confidence level for total dry eye sufferers, ±6.5 for Rx Users, and ±6.6 for OTC Only users. This credible interval will be wider among subsets of the surveyed population of interest. Article content All sample surveys and polls, whether or not they use probability sampling, are subject to other multiple sources of error which are most often not possible to quantify or estimate, including, but not limited to coverage error, error associated with nonresponse, error associated with question wording and response options, and post-survey weighting and adjustments Article content About Bausch + Lomb Article content Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from birth through every phase of life. Its comprehensive portfolio of approximately 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with approximately 13,500 employees and a presence in approximately 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario, with corporate offices in Bridgewater, New Jersey. For more information, visit and connect with us on Facebook, Instagram, LinkedIn, X and YouTube. Article content Article content Article content Article content Contacts Article content Media: Article content Article content Kristy Marks Article content Article content Article content Article content
Yahoo
30-06-2025
- Business
- Yahoo
The Top 5 Analyst Questions From Bausch + Lomb's Q1 Earnings Call
Bausch + Lomb's first quarter results disappointed investors as both revenue and adjusted earnings fell short of Wall Street's expectations, leading to a sharp market reaction. Management attributed the underperformance primarily to supply disruptions from a voluntary recall of its enVista intraocular lenses and weaker results in the high-margin U.S. Generics pharmaceutical business. CEO Brent Saunders noted that, despite these setbacks, 'our core business is performing well,' highlighting continued strength in the company's Vision Care and Surgical divisions. Ongoing headwinds in Pharmaceuticals, especially in generics, and the financial impact of the recall weighed on overall margins and profitability. Is now the time to buy BLCO? Find out in our full research report (it's free). Revenue: $1.14 billion vs analyst estimates of $1.15 billion (3.5% year-on-year growth, 0.7% miss) Adjusted EPS: -$0.07 vs analyst estimates of $0.02 (significant miss) Adjusted EBITDA: $126 million vs analyst estimates of $163.4 million (11.1% margin, 22.9% miss) The company lifted its revenue guidance for the full year to $5.05 billion at the midpoint from $4.98 billion, a 1.5% increase EBITDA guidance for the full year is $875 million at the midpoint, below analyst estimates of $921.9 million Operating Margin: -7.3%, down from 0.5% in the same quarter last year Constant Currency Revenue rose 5.2% year on year (20.2% in the same quarter last year) Market Capitalization: $4.25 billion While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention. Patrick Wood (Morgan Stanley) asked about the impact and customer response to the enVista recall. CEO Brent Saunders reported that most customers appreciated the company's transparency and commitment to safety, with many planning to resume use as soon as supply is restored. Young Li (Jefferies) inquired about consumer demand trends, particularly in the U.S. and China. Saunders explained that consumption remained strong, with little sign of discretionary pullback, but noted ongoing retailer inventory destocking as a near-term factor. Joanne Wuensch (Citi) requested updates on the contact lens pipeline and market dynamics. Saunders and Head of R&D Yehia Hashad highlighted the progression of biomimetic lens and myopia control programs, emphasizing that new products are designed to leverage existing manufacturing infrastructure. Unidentified Analyst (Wells Fargo) sought clarity on the timing and magnitude of tariff impacts. CFO Sam Eldessouky projected that immediate actions would shield margins in the first half, with more balanced exposure in the second half, depending on additional mitigation steps. Robbie Marcus (JPMorgan) questioned the exclusion of tariffs from official guidance and potential covenant risks. Saunders and Eldessouky underscored the fluidity of tariff policy and expressed confidence in the company's ability to remain in compliance through ongoing mitigation. In the upcoming quarters, our analysts will be watching (1) the pace of enVista IOL restocking and adoption in the U.S. and international markets, (2) the effectiveness of management's tariff mitigation efforts and any developments in trade policy, and (3) continued sales momentum in flagship brands like MIEBO, XIIDRA, and Daily SiHy contact lenses. Progress in advancing clinical pipeline assets and the launch timing for new IOL and contact lens products will also be important indicators. Bausch + Lomb currently trades at $12.48, down from $13.72 just before the earnings. Is the company at an inflection point that warrants a buy or sell? Find out in our full research report (it's free). Market indices reached historic highs following Donald Trump's presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth. While this has caused many investors to adopt a "fearful" wait-and-see approach, we're leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today. Error al recuperar los datos Inicia sesión para acceder a tu cartera de valores Error al recuperar los datos Error al recuperar los datos Error al recuperar los datos Error al recuperar los datos
National Post
30-06-2025
- Business
- National Post
Bausch + Lomb Will Release Second-Quarter 2025 Financial Results on July 30 and Hold Investor Day on Nov. 13
Article content Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its second-quarter financial results on Wednesday, July 30, 2025. The company will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the start of the call. Article content Bausch + Lomb will hold an investor day on Thursday, Nov. 13, 2025, where the company will provide a business update and highlight its innovative product pipeline. Additional details will follow closer to the event. Article content Article content Second-Quarter Conference Call Details Article content About Bausch + Lomb Article content Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from birth through every phase of life. Its comprehensive portfolio of approximately 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with approximately 13,500 employees and a presence in approximately 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario, with corporate offices in Bridgewater, New Jersey. For more information, visit Article content , Article content Instagram Article content , Article content LinkedIn Article content , Article content X Article content and Article content YouTube Article content . Article content © 2025 Bausch + Lomb. Article content Article content Article content Article content Contacts Article content Media Contact: Article content Chris Clark Article content Article content Article content Article content Article content Article content
National Post
26-06-2025
- Business
- National Post
Bausch + Lomb Announces Closing of Upsized €675 Million Senior Secured Notes Offering and Partial Credit Agreement Refinancing, Including Upsized $2.325 Billion Term Loan Facility
Article content VAUGHAN, Ontario — Bausch + Lomb Corporation (NYSE/TSX: BLCO) ('Bausch + Lomb' or the 'company'), a leading global eye health company dedicated to helping people see better to live better, today announced that its subsidiaries, Bausch+Lomb Netherlands B.V. and Bausch & Lomb Incorporated (collectively, the 'Issuers'), have closed the upsized offering of €675 million aggregate principal amount of senior secured floating rate notes due 2031 (the 'Notes'). In addition, the company announced that it has completed a partial refinancing of its credit agreement, and in connection with such refinancing, it has entered into a third amendment (the 'Third Amendment') to its existing credit agreement providing for a $2.325 billion term B loan facility maturing in 2031 (the 'New Term B Loans') and an $800 million revolving credit facility maturing in 2030 (subject to customary 'springing' maturity provisions) (the 'New Revolving Credit Facility'). Article content The Notes bear interest at the rate of three-month EURIBOR (with a 0% floor) plus 3.875% per year, reset quarterly, and will mature on January 15, 2031. The Notes were sold to investors at a price of 99.500% of the principal amount thereof. Article content Article content The Notes are guaranteed by the company and each of the company's subsidiaries (other than the Issuers) that are guarantors under the company's credit agreement and are secured on a first priority basis by liens on the same assets that secure the obligations under the company's credit agreement and the company's outstanding senior secured notes. Article content The amortization rate for the New Term B Loans is 1.00% per annum and the first installment shall be payable on September 30, 2025. Pursuant to the Third Amendment, the initial rate of interest applicable to the New Term B Loans is (i) 4.25% for the New Term B Loans that are SOFR Loans and (ii) 3.25% for New Term B Loans that are ABR Loans. The rate of interest applicable to the New Revolving Credit Facility remains the same as that applicable to the existing revolving credit facility. The Third Amendment includes certain other modifications to the credit agreement, including increased financial covenant levels and other changes providing for additional transaction flexibility. Article content The company used the net proceeds from the Notes offering and the New Term B Loans to repay in full the outstanding borrowings under its existing revolving credit facility, to refinance in full the outstanding term A loans due 2027 and term B loans due 2027 and to pay related fees and expenses. Article content The Notes are not registered under the Securities Act of 1933, as amended ('Securities Act'), or any state securities law and may not be offered or sold in the United States absent registration or an applicable exemption from registration under the Securities Act and applicable state securities laws. The Notes were offered in the United States only to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act and outside the United States to non-U.S. persons pursuant to Regulation S under the Securities Act. The Notes were not and will not be qualified for sale to the public by prospectus under applicable Canadian securities laws and, accordingly, any offer and sale of the Notes in Canada must be made on a basis which is exempt from the prospectus requirements of such securities laws. Article content About Bausch + Lomb Article content Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from birth through every phase of life. Its comprehensive portfolio of approximately 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with approximately 13,500 employees and a presence in approximately 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario, with corporate offices in Bridgewater, New Jersey. Article content Forward-looking Statements Article content This news release may contain forward-looking information and statements within the meaning of applicable securities laws (collectively, 'forward-looking statements'). Forward-looking statements may generally be identified by the use of the words 'anticipates,' 'seeks,' 'expects,' 'plans,' 'should,' 'could,' 'would,' 'may,' 'will,' 'believes,' 'potential,' 'pending' or 'proposed' and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in Bausch + Lomb's filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators (including the company's Annual Report on Form 10-K for the year ended Dec. 31, 2024 and its most recent quarterly filings). In addition, certain material factors and assumptions have been applied in making these forward-looking statements, including the assumption that the risks and uncertainties discussed in such filings will not cause actual results or events to differ materially from those described in these forward-looking statements. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch + Lomb undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law. Article content Article content Article content Media Contacts Article content : Article content Article content T.J. Crawford Article content Article content Article content Article content (908) 705-2851 Article content Investor Contacts Article content : Article content Article content George Gadkowski Article content Article content Article content Article content
Yahoo
23-06-2025
- Business
- Yahoo
Barclays Cut Bausch & Lomb Target to $16, Keeping Rating Neutral in Early June
Barclays lowered its price target on Bausch & Lomb (NYSE: BLCO) from $19 to $16 on June 6, maintaining an Equalweight rating. The revision reflects a more cautious outlook on the company's near-term financial performance. The firm trimmed its next twelve-month EBITDA forecast to $996 million, down from $1.04 billion. As a result, the valuation multiple used in their model was reduced to 10.5x EV/EBITDA, just above the current trading level but below the stock's post-spin average of 11x. A medical professional wearing an eye mask, demonstrating the effectiveness of Bausch Health's ophthalmic solutions. Barclays also adjusted its sales and earnings projections. Sales estimates were shaved by less than 1% annually starting in 2025, in line with company guidance. The changes are driven in part by the expected impact of the Inflation Reduction Act and formulary shifts affecting Xiidra. EPS estimates saw a steeper drop, down around 12% for 2025, when guidance changes and the fallout from the enVista recall are factored in. For 2026 and beyond, earnings projections have been lowered by 13–14% annually. We previously shared a . While we acknowledge the potential of BLCO as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
